S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Musk May Have Just Changed Everything (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Musk May Have Just Changed Everything (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Musk May Have Just Changed Everything (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Musk May Have Just Changed Everything (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
NASDAQ:DMTK

DermTech (DMTK) Stock Forecast, Price & News

$1.44
-0.04 (-2.70%)
(As of 09/29/2023 ET)
Compare
Today's Range
$1.44
$1.54
50-Day Range
$1.44
$3.53
52-Week Range
$1.44
$6.44
Volume
249,211 shs
Average Volume
226,234 shs
Market Capitalization
$48.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.33

DermTech MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
339.8% Upside
$6.33 Price Target
Short Interest
Bearish
15.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.22mentions of DermTech in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$42,134 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.56) to ($2.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

630th out of 972 stocks

Medical Laboratories Industry

16th out of 25 stocks


DMTK stock logo

About DermTech (NASDAQ:DMTK) Stock

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

DMTK Price History

DMTK Stock News Headlines

Elon Did It Again: This Could be Bigger than Tesla
Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.
One penny stock I’m having second thoughts about
Elon Did It Again: This Could be Bigger than Tesla
Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.
Insider Sell: DermTech Inc CFO Kevin Sun Sells 9,616 Shares
DermTech Appoints Mark Aguillard as Chief Commercial Officer
DermTech Reports Second-Quarter 2023 Financial Results
DermTech (DMTK) Gets a Buy from Craig-Hallum
Why DermTech Shares Are Rising Today
See More Headlines
Receive DMTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DermTech and its competitors with MarketBeat's FREE daily newsletter.

DMTK Company Calendar

Last Earnings
8/03/2023
Today
10/01/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DMTK
Fax
N/A
Employees
278
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.33
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+339.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-116,680,000.00
Net Margins
-853.02%
Pretax Margin
-853.02%

Debt

Sales & Book Value

Annual Sales
$14.52 million
Book Value
$4.38 per share

Miscellaneous

Free Float
31,981,000
Market Cap
$48.53 million
Optionable
Not Optionable
Beta
2.22
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Kevin Sun M.B.A. (Age 45)
    CFO, Treasurer & Sec.
    Comp: $461.92k
  • Ms. Claudia IbarraMs. Claudia Ibarra (Age 61)
    Chief Operating Officer
    Comp: $414.09k
  • Mr. Ray Akhavan Esq. (Age 54)
    J.D., Gen. Counsel
    Comp: $413.06k
  • Mr. Bret Christensen (Age 52)
    Pres, CEO & Director
  • Mr. William W. Zondler
    Chief Information Officer
  • Mr. Steve E. Kunszabo
    Sr. Director of Investor Relations
  • Ms. Jennifer Eilemberg
    Chief Compliance Officer
  • Mr. Ray Bassi
    VP of Sales
  • Dr. Burkhard Jansen M.D. (Age 57)
    Chief Medical Affairs Officer
  • Mr. Daniel Visage
    Sr. VP of Payer Access













DMTK Stock - Frequently Asked Questions

Should I buy or sell DermTech stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DMTK shares.
View DMTK analyst ratings
or view top-rated stocks.

What is DermTech's stock price forecast for 2023?

4 Wall Street research analysts have issued 12-month price targets for DermTech's shares. Their DMTK share price forecasts range from $5.00 to $8.00. On average, they anticipate the company's stock price to reach $6.33 in the next year. This suggests a possible upside of 339.8% from the stock's current price.
View analysts price targets for DMTK
or view top-rated stocks among Wall Street analysts.

How have DMTK shares performed in 2023?

DermTech's stock was trading at $1.77 at the start of the year. Since then, DMTK stock has decreased by 18.6% and is now trading at $1.44.
View the best growth stocks for 2023 here
.

When is DermTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our DMTK earnings forecast
.

How were DermTech's earnings last quarter?

DermTech, Inc. (NASDAQ:DMTK) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.95) by $0.04. The firm had revenue of $3.98 million for the quarter, compared to analyst estimates of $3.55 million. DermTech had a negative trailing twelve-month return on equity of 99.14% and a negative net margin of 853.02%.

What other stocks do shareholders of DermTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE), CrowdStrike (CRWD), DocuSign (DOCU), ONEOK (OKE), Intel (INTC), U.S. Xpress Enterprises (USX), Valero Energy (VLO), Hello Group (MOMO), AVEO Pharmaceuticals (AVEO) and Camping World (CWH).

What is DermTech's stock symbol?

DermTech trades on the NASDAQ under the ticker symbol "DMTK."

How do I buy shares of DermTech?

Shares of DMTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DermTech's stock price today?

One share of DMTK stock can currently be purchased for approximately $1.44.

How much money does DermTech make?

DermTech (NASDAQ:DMTK) has a market capitalization of $48.53 million and generates $14.52 million in revenue each year. The company earns $-116,680,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis.

How many employees does DermTech have?

The company employs 278 workers across the globe.

How can I contact DermTech?

DermTech's mailing address is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. The official website for the company is www.dermtech.com. The company can be reached via phone at (858) 450-4222 or via email at investorrelations@dermtech.com.

This page (NASDAQ:DMTK) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -